Silence Therapeutics plc (Silence) is a biotechnology research and development company. Silence, along with its subsidiaries, is engaged in research and development of pharmaceutical products. The Company discovers, develops and delivers ribonucleic acid (RNA) interference (RNAi) therapeutics for the treatment of serious diseases. Silence operates two segments: RNAi therapeutics and Immunotherapy. The Company has two licence agreements with partner Quark Pharmaceuticals, for products PF 04523655 and QPI 1002, both of which are in development in two different therapeutic indications. The Company�s product pipeline includes PF 4523655 for diabetic macular edema, PF 4523655 for age related macular degeneration, QPI 1002 for prevention of delayed graft function, QPI 1002 for Acute Kidney Injury, Aut027 for Solid Tumours, and Atu111 for Acute Lung Injury.